Variable Lymphocyte Receptor B Technologies - Are They Ready for Prime Time?

IF 2.9 4区医学 Q3 IMMUNOLOGY

Immunological Investigations Pub Date : 2025-07-01 Epub Date: 2025-02-12 DOI:10.1080/08820139.2025.2462536

Arundhati G Nair, Götz R A Ehrhardt, Eyal Grunebaum

{"title":"Variable Lymphocyte Receptor B Technologies - Are They Ready for Prime Time?","authors":"Arundhati G Nair, Götz R A Ehrhardt, Eyal Grunebaum","doi":"10.1080/08820139.2025.2462536","DOIUrl":null,"url":null,"abstract":"Objective: To review the current and the potential research and clinical use of VLRBs.Methods: A literature search was conducted for English studies published in the past 20 years using the terms \"Variable Lymphocyte Receptor,\" \"VLR,\" \"VLRB\" or \"Repebody.\" Only primary reports were included.Results: VLRB-based technologies are currently being investigated for diagnosis, imaging, and treatment of diverse conditions including solid organ and hematological malignancies, infectious diseases, autoimmunity, and degenerative and metabolic disorders. VLRB mAbs can be used to directly recognize disease biomarkers, such as B cells from chronic lymphocytic leukemia, or to deliver drugs to the brain or cancer cells. The VLRB C-terminal multimerization domain has been utilized to create vaccines while VLR-based chimeric antigen receptor (CAR) T cell constructs are being investigated for cancer therapies.Conclusions: The extensive knowledge gained with VLRB mAbs in diverse in vitro and in vivo models emphasizes their promise for translation into clinical applications and readiness for prime time.","PeriodicalId":13387,"journal":{"name":"Immunological Investigations","volume":" ","pages":"637-657"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunological Investigations","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820139.2025.2462536","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To review the current and the potential research and clinical use of VLRBs.

Methods: A literature search was conducted for English studies published in the past 20 years using the terms "Variable Lymphocyte Receptor," "VLR," "VLRB" or "Repebody." Only primary reports were included.

Results: VLRB-based technologies are currently being investigated for diagnosis, imaging, and treatment of diverse conditions including solid organ and hematological malignancies, infectious diseases, autoimmunity, and degenerative and metabolic disorders. VLRB mAbs can be used to directly recognize disease biomarkers, such as B cells from chronic lymphocytic leukemia, or to deliver drugs to the brain or cancer cells. The VLRB C-terminal multimerization domain has been utilized to create vaccines while VLR-based chimeric antigen receptor (CAR) T cell constructs are being investigated for cancer therapies.

Conclusions: The extensive knowledge gained with VLRB mAbs in diverse in vitro and in vivo models emphasizes their promise for translation into clinical applications and readiness for prime time.

查看原文本刊更多论文

可变淋巴细胞受体B技术——它们准备好进入黄金时代了吗？

目的：综述VLRBs的研究现状和应用前景。方法：用“可变淋巴细胞受体”、“VLR”、“VLRB”或“重复体”等术语对近20年来发表的英文研究进行文献检索。只包括初步报告。结果：基于vlrb的技术目前正在研究用于多种疾病的诊断、成像和治疗，包括实体器官和血液系统恶性肿瘤、传染病、自身免疫性疾病、退行性疾病和代谢疾病。VLRB单克隆抗体可用于直接识别疾病生物标志物，如来自慢性淋巴细胞白血病的B细胞，或用于向脑细胞或癌细胞输送药物。VLRB c端多聚结构域已被用于制造疫苗，而基于vlr的嵌合抗原受体（CAR） T细胞构建正在研究用于癌症治疗。结论：VLRB单克隆抗体在各种体外和体内模型中获得的广泛知识强调了它们在转化为临床应用和黄金时间准备方面的前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunological Investigations 医学-免疫学

CiteScore

5.50

自引率

7.10%

发文量

审稿时长

3 months

期刊介绍： Disseminating immunological developments on a worldwide basis, Immunological Investigations encompasses all facets of fundamental and applied immunology, including immunohematology and the study of allergies. This journal provides information presented in the form of original research articles and book reviews, giving a truly in-depth examination of the latest advances in molecular and cellular immunology.